Home>Media>Newsroom Media Newsroom - 2025 Glenmark Pharma reports consolidated revenue growth of 35.1%, EBITDA margin of 17.7% and PAT margin of 10.3% YoY for Q3 FY2025 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Latanoprost Ophthalmic Solution 0.005% 14 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1% 12 FEB 2025 | READ MORE Cosmo and Glenmark Announce UK MHRA Approval of Winlevi® for Treatment of Acne 10 FEB 2025 | READ MORE Glenmark Pharmaceuticals Inc., USA launches Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules 21 JAN 2025 | READ MORE Year – 2025 Year – 2024 Year – 2023 Year – 2022 Year – 2021 Year – 2020 Year – 2019 Year – 2018 Year – 2017 Year – 2016 Year – 2015
